본문으로 건너뛰기
Stock Expert AI

Simplify Propel Opportunities ETF (SURI) Holdings

이 페이지는 영어 원문에서 AI로 기계 번역되었습니다. 영어 버전이 기준입니다. 영어 버전 읽기

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

빠른 답변

Simplify Propel Opportunities ETF (SURI) has a last stored price of $16.63, as of the Oct 23, 2026 trading session. It has a 2.82% expense ratio and $74M in assets under management.

Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Plains GP Holdings LP Class A (PAGP) at 36.76%, and the largest sector allocation is Healthcare at 59.5%.

Simplify Propel Opportunities ETF (SURI) ETF — Price, Holdings & Analysis

ETF 개요

The Simplify Propel Opportunities ETF (SURI) aims for long-term capital growth by investing in biotech, pharma, health care technology, and life science companies. SURI is designed for investors seeking exposure to potentially undervalued companies within the health sciences sector. The fund is sub-advised by Propel, leveraging their scientific and commercial expertise to identify promising investment opportunities. SURI's portfolio consists of 19 holdings, with a significant allocation to Plains GP Holdings LP Class A (PAGP) at 36.76%. Other top holdings include Achieve Life Sciences Inc (6.92%), Phathom Pharmaceuticals Inc Ordinary shares (4.93%), Milestone Pharmaceuticals Inc (3.30%), and Abeona Therapeutics Inc (3.28%). The fund's sector allocation is heavily weighted towards Healthcare (59.5%) and Energy (40.5%). SURI's investment strategy focuses on identifying companies with significant capital appreciation potential within the health sciences industry.

위험 지표

SURI presents several risk considerations for investors. The fund's high expense ratio of 2.82% can create a significant drag on returns, especially when compared to passively managed ETFs with lower fees. The fund exhibits concentration risk, with a substantial portion of its assets allocated to its top holding, Plains GP Holdings LP Class A (PAGP), at 36.76%. This concentrated exposure could amplify the impact of any adverse events affecting this company. Sector concentration is also a factor, with approximately 59.5% of the portfolio invested in the Healthcare sector and 40.5% in Energy, making it vulnerable to sector-specific downturns. With a 3-year beta of 1.29, SURI demonstrates higher volatility than the overall market. Investors should carefully consider these risks before investing in SURI. Past performance does not guarantee future results.
  • 베타: 1.29

운용보수율

2.82%

SURI은(는) 무엇을 보유하고 있나요?

보유 종목비중
Plains GP Holdings LP Class A (PAGP)36.76%
Achieve Life Sciences Inc (ACHV)6.92%
Phathom Pharmaceuticals Inc Ordinary shares (PHAT)4.93%
Milestone Pharmaceuticals Inc (MIST)3.30%
Abeona Therapeutics Inc (ABEO)3.28%
Celldex Therapeutics Inc (CLDX)3.28%
Delcath Systems Inc (DCTH)2.98%
Oculis Holding AG (OCS)2.79%
Viridian Therapeutics Inc (VRDN)2.75%
Inventiva SA ADR (IVA)2.11%

이 펀드 데이터는 45일 이상 지났습니다. 최신 보유 종목은 발행사에서 확인하세요.

펀드는 어떻게 배분되어 있나요?

섹터비중
헬스케어59.5%
에너지40.5%
국가비중
기타4.1%
미국78.1%
덴마크0.8%
네덜란드0.7%
스위스2.5%
캐나다10.2%
프랑스2.0%
중국0.2%
영국1.4%

배당수익률

0.00%

질문 및 답변

What is SURI and what does it track?

The Simplify Propel Opportunities ETF (SURI) is an actively managed equity ETF that aims to provide long-term capital growth by investing in biotech, pharma, health care technology, and life science companies.

The fund seeks to identify companies that are believed to be overlooked by investors, presenting significant opportunities for capital appreciation.

What is the expense ratio for SURI?

The expense ratio for the Simplify Propel Opportunities ETF (SURI) is 2.82%. This means that for every $10,000 invested in the fund, investors will pay $282 in annual fees to cover the fund's operating expenses.

This expense ratio is significantly higher than the category average for equity ETFs, which is approximately 0.44%.

What are the top holdings in SURI?

As of 2026-03-15, the top holdings in the Simplify Propel Opportunities ETF (SURI) are: Plains GP Holdings LP Class A (PAGP) at 36.76%, Achieve Life Sciences Inc at 6.92%, Phathom Pharmaceuticals Inc Ordinary shares at 4.93%, Milestone Pharmaceuticals Inc at…

3.30%, and Abeona Therapeutics Inc at 3.28%.

Is SURI a good long-term investment?

Whether SURI is a suitable long-term investment depends on an individual investor's risk tolerance, investment goals, and time horizon. SURI offers exposure to biotech, pharma, health care technology, and life science companies, potentially providing growth opportunities.

However, the fund's high expense ratio of 2.82% can negatively impact long-term returns.

How does SURI compare to similar ETFs?

SURI differentiates itself from similar ETFs through its active management and focus on overlooked opportunities within the health sciences sector. Its expense ratio of 2.82% is considerably higher than many passively managed healthcare ETFs.

With AUM of $0.07 billion, SURI is relatively small compared to established healthcare ETFs.

Does SURI pay dividends?

As of 2026-03-15, the Simplify Propel Opportunities ETF (SURI) has a dividend yield of 0.00%. This indicates that the fund does not currently distribute any dividends to its shareholders.

Investors seeking income-generating investments may want to consider other ETFs with a history of dividend payments. However, it is important to note that dividend yields can fluctuate over time and are not guaranteed.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.

이 페이지는 기계가 작성했으며, 페이지별 사람 검수는 거치지 않았습니다. 편집 관리는 체계 차원에서 이루어집니다: 규칙과 출처를 점검하며, 개별 페이지는 점검하지 않습니다.